| Domain | Key findings | Ontology suggestions | Evidence strength/type |
|---|---|---|---|
| Identity / disease class | Autosomal dominant nonsyndromic hearing loss 7 (DFNA7) is a Mendelian, nonsyndromic sensorineural hearing-loss entity associated with **LMX1A**; Open Targets lists **MONDO:0011074** for this disease-target association. Evidence is from aggregated disease resources plus small family-based human studies, not EHR-derived population datasets. (pqac-00000000, pqac-00000010) | MONDO:0011074; nonsyndromic hearing impairment concept | Moderate; curated disease-resource + human genetic studies |
| Locus / gene | Cytogenetic location reported as **1q23.3**; gene **LMX1A** encodes a LIM-homeobox transcription factor important for inner-ear development and maintenance. (pqac-00000000, pqac-00000010, pqac-00000019) | Gene: LMX1A; UBERON: inner ear, cochlea, vestibular system | Strong for gene-disease association; human + model evidence |
| Inheritance | Predominantly **autosomal dominant**; several families show vertical transmission, and **de novo** heterozygous variants have also been reported. (pqac-00000002, pqac-00000003, pqac-00000008) | HP: Autosomal dominant inheritance | Strong; human pedigree/segregation evidence |
| Core phenotype | Core presentation is **sensorineural hearing loss (SNHL)**, usually bilateral but often **asymmetric**, commonly with **downsloping/high-frequency** configuration and variable severity from mild to profound. Suggested HPO terms: hearing impairment, sensorineural hearing impairment, asymmetric hearing impairment, progressive hearing impairment, high-frequency/sloping audiogram. (pqac-00000001, pqac-00000008, pqac-00000010, pqac-00000013) | HPO suggestions: sensorineural hearing impairment; progressive hearing impairment; asymmetric hearing impairment; high-frequency hearing impairment | Strong; human clinical cohorts |
| Onset / temporal course | Onset is highly variable: congenital/prelingual cases and postlingual cases are both reported; 2023 review summarizes onset from **1st–6th decade** with progressive course. In the 2018 series, onset ranged from congenital to 35 years and was often in the 2nd–3rd decade. Disease is typically lifelong, not remitting. (pqac-00000010, pqac-00000011, pqac-00000013) | HPO suggestions: congenital onset; childhood onset; adult onset; progressive course | Strong; review + primary human data |
| Vestibular involvement | Vestibular dysfunction is a recurrent but variable feature: the 2018 study states **about half** of affected individuals had vestibular dysfunction/symptoms; abnormalities included absent cVEMPs and caloric abnormalities, with symptoms appearing in adulthood and seeming progressive. In the 2022 cohort, one patient had hearing fluctuation with intermittent vertigo/headache suggestive of Menière-like episodes. (pqac-00000011, pqac-00000012, pqac-00000008) | HPO suggestions: vestibular dysfunction, vertigo, abnormal caloric test, absent vestibular evoked myogenic potentials | Moderate-strong; small human cohorts with formal vestibular testing |
| Key pathogenic variants | Reported heterozygous disease-associated variants include **c.290G>C (p.Cys97Ser)**, **c.721G>C (p.Val241Leu)**, **c.595A>G (p.Arg199Gly)**, **c.622C>T (p.Arg208*)**, **c.887dup (p.Gln297Thrfs*41)**, **c.719A>G (p.Gln240Arg)**, **c.721G>A (p.Val241Met)**, and **c.331del (p.Gln111Argfs*7)**. Most are ultra-rare/absent in population databases in the cited cohorts. (pqac-00000002, pqac-00000003, pqac-00000006, pqac-00000008, pqac-00000012) | Variant classes: missense, nonsense, frameshift; germline heterozygous variants | Strong for listed reported variants; human molecular studies |
| Mechanism / pathophysiology | Human functional data support **haploinsufficiency** rather than dominant-negative effect for dominant LMX1A hearing loss. Reduced transcriptional activity correlates with more severe phenotype; p.Arg199Gly had near-abolished activity and severe congenital SNHL, whereas p.Cys97Ser/p.Val241Leu retained more activity and caused later progressive NSHL. Upstream/downstream developmental links from models include regulation involving **Lmo4**, **Bmp6**, **Atoh1**, **Pax2**, Wnt-related patterning, and strial differentiation markers. (pqac-00000003, pqac-00000005, pqac-00000014, pqac-00000015, pqac-00000016, pqac-00000018, pqac-00000019) | GO suggestions: DNA-binding transcription factor activity; inner ear development; sensory epithelium development; stria vascularis development | Strong for transcriptional dysfunction/haploinsufficiency; human in vitro + mouse developmental models |
| Anatomy / tissues / cell types | Primary anatomy: **cochlea**, **organ of Corti**, **stria vascularis**, **Reissner’s membrane**, **endolymphatic duct/sac**, vestibular organs, and spiral ganglion/cerebellar-brainstem auditory circuitry in models. Cell-type suggestions include **hair cells**, **marginal cells**, **intermediate cells**, **spiral ganglion neurons**, and non-sensory epithelial cells. Single-cell evidence identified an **Lmx1a-positive type I spiral ganglion neuron** population in mouse cochlea. (pqac-00000016, pqac-00000017, pqac-00000018, pqac-00000020) | UBERON suggestions: cochlea, organ of Corti, stria vascularis, vestibular labyrinth; CL suggestions: hair cell, marginal cell, intermediate cell, spiral ganglion neuron; GO CC suggestions: nucleus | Moderate-strong; mostly model-organism anatomy/cell evidence |
| Diagnostics | Current diagnosis is based on audiologic phenotyping, serial follow-up for progression/asymmetry, vestibular testing when symptomatic, temporal-bone CT to exclude malformations/other causes, and molecular testing using hearing-loss gene panels or **WES** with segregation/ACMG interpretation; **WGS** is a reasonable escalation in unsolved hearing-loss cases generally, but no DFNA7-specific testing guideline was found. (pqac-00000011, pqac-00000012, pqac-00000008) | HPO suggestions for workup: abnormal auditory brainstem response; abnormal vestibular testing | Moderate; disease-specific cohort methods + general hearing-loss practice inference |
| Treatment / real-world care | No DFNA7-specific drug or gene therapy was identified. Real-world management is supportive: **hearing aids** for milder/moderate disease and **cochlear implantation (CI)** for advanced loss. In the 2022 LMX1A series, one patient underwent unilateral CI with significant speech-perception improvement at 3 and 6 months post-op; the same paper notes favorable CI outcomes in LMX1A-related cases. (pqac-00000008, pqac-00000006) | NCIT suggestions: hearing aid device; cochlear implantation; vestibular rehabilitation; genetic counseling | Moderate; small human rehabilitation cohort |
| Epidemiology / population | Disease-specific prevalence and incidence are **not available**. Evidence comes from very small reported series: 2018 described **two Dutch families**; 2022 identified **nine patients from six LMX1A-associated families** in two tertiary centers. No robust penetrance, sex ratio, founder mutation, carrier frequency, or geographic prevalence data were found. (pqac-00000002, pqac-00000008) | Rare disease; familial autosomal dominant hearing loss | Limited; case-series level |
| Environmental factors / modifiers | No validated DFNA7-specific environmental risk or protective factors were identified. The 2018 study excluded obvious acquired causes of hearing loss in examined subjects, but formal gene-environment interactions remain unproven. General hearing-conservation advice is still clinically sensible but is not DFNA7-specific evidence. (pqac-00000012, pqac-00000013) | HPO/Exposure suggestions not disease-specific | Limited; absence-of-evidence statement |
| Model organisms | Mouse **Lmx1a** null/dreher models show severe cochlear and vestibular malformations, loss/fusion of sensory epithelia, abnormal stria vascularis formation, absent endocochlear potential, and deafness; these models are mechanistically informative but more severe than human dominant DFNA7. Heterozygous mice may have normal hearing, highlighting translational limitations. (pqac-00000001, pqac-00000016, pqac-00000017, pqac-00000018) | NCBI Taxon suggestion: Mus musculus; phenotype suggestions: deafness, vestibular dysfunction | Strong for mechanism; indirect for exact human phenotype |
| Evidence gaps / curation cautions | Gaps include: original historical linkage details not fully retrieved here; no disease-specific epidemiology; no validated penetrance estimates; no confirmed modifier genes, protective factors, omics biomarkers, or epigenetic signatures; no registered DFNA7-specific interventional trial identified; and several ontology IDs beyond MONDO/HPO high-level terms would require manual validation before KB ingestion. (pqac-00000000, pqac-00000008, pqac-00000021) | Manual validation recommended for HPO/GO/CL/UBERON mappings | Strong for identified gaps because evidence is sparse/no direct studies |


*Table: This table summarizes high-yield knowledge-base facts for autosomal dominant nonsyndromic hearing loss 7 associated with LMX1A, including phenotype, mechanism, diagnostics, treatment, and evidence gaps. It is designed as a compact curation aid grounded in the available cited human and model-organism evidence.*